AMRX vs PEG · P/E 44, rev $2.79B vs P/E 18, rev $10.29B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Public Service Enterprise Group Inc (PEG) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Public Service Enterprise Group Inc (PEG) is a utilities - regulated electric company listed on NYSE.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported PEG revenue for 2024-12-31 was $10.29B. Net income was $1.77B. Revenue was down 8.4% from 2023-12-31 to 2024-12-31. PEG currently screens at market cap $39.57B and trailing P/E 17.6.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. PEG currently screens at market cap $39.57B and trailing P/E 17.6.
Not investment advice. Open the AMRX and PEG stock pages for the full models.
Not investment advice.